Physician profile
Hazel Wiley
NPI 1821208794
$20,483.87
in general payments reported to CMS, 2019-2025
60 companies · $5,084 in 2025
The $5,084 reported for 2025 was more than what 85% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,504 · 2020: $1,472 · 2021: $3,154 · 2022: $2,916 · 2023: $3,260 · 2024: $3,095 · 2025: $5,084.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $125 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $20.88.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,292.95 |
| Education | $125.06 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $20.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $1,892.66 | 2019-2025 | Mavenclad, Mavenclad |
| Ucb, INC. | $1,852.64 | 2019-2025 | Briviact, Nayzilam, Fintepla |
| Abbvie INC. | $1,367.76 | 2021-2025 | Ubrelvy, Qulipta, Botox |
| Biogen, INC. | $1,174.93 | 2019-2025 | Leqembi, Vumerity, Tysabri |
| Biohaven Pharmaceuticals, INC. | $1,104.04 | 2020-2021 | |
| Lilly USA, LLC | $1,073.26 | 2019-2025 | Amyvid, Kisunla |
| Eisai INC. | $1,065.73 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $980.75 | 2019-2025 | Austedo Xr, Austedo, Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $826.02 | 2023-2025 | Rexulti, Nuedexta |
| Amneal Pharmaceuticals LLC | $797.19 | 2019-2025 | Crexont, Rytary, Ongentys |
| Mdd US Operations, LLC | $706.19 | 2019-2025 | Apokyn, Gocovri, Apokyn |
| Genzyme Corporation | $558.22 | 2019-2022 | |
| Sk Life Science, INC. | $479.29 | 2020-2025 | |
| Argenx US, INC. | $456.30 | 2023-2025 | Vyvgart Hytrulo, Vyvgart |
| Neurelis, INC. | $443.27 | 2021-2025 | Valtoco |
Show all 60 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hazel Wiley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.